MS PHARMA’s Post

Zeta Pharma Strengthens Middle East and Africa Presence with New Facility in Saudi Arabia Zeta Pharma has partnered with Alam AlSayedla Company to establish a pharmaceutical manufacturing facility in Saudi Arabia. The agreement was finalized at CPHI KSA, in presence of the Saudi Minister of Health. This expansion enhances Zeta Pharma’s ability to meet the healthcare needs of the Middle East and Africa. The new facility will produce essential medications, improving access and supporting the region's well-being. Zeta Pharma committed to delivering impactful healthcare solutions across the region.

Discover the thriving biotech landscape in the Middle East and unlock incredible opportunities! Join this unmissable session to gain valuable insights and stay ahead in this dynamic market.

I'm delighted to share that Teva Pharmaceuticals Europe won the “Best Global Campaign for Generics and Biosimilars” at the 11th Global Generics and Biosimilars Awards during CPhI Worldwide week in Milan. Our award-winning campaign was built around our in-house-developed report, “The Critical Medicines Health Check 2024”, released in March. The report highlights the current state of the European generic medicines segment, revealing a concerning trend: a 12% increase in the withdrawal of generic medicines from the market over the past decade, along with a 3% decrease in the launch of new generic products. Congratulations to our #TevaTeam for this recognition and their outstanding contributions to innovative policy and advocacy approaches across Europe's pharmaceutical sector. 👉 Read more:  https://lnkd.in/eYR_8RaJ Erick Tyssier Josef Kunrt Stefanie Kitzinger Fiona Cohen Philippe Drechsle Antje-Katrin Weigelt    #TevaPharm #Proud #Generics #Biosimilars #Healthcare #CPhI2024 #WeAreAllInForBetterHealth

We are proud to announce the signing of a Memorandum of Understanding (MOU) between #SPIMACO and #Nahdi Medical Company, uniting efforts to advance healthcare solutions and pharmaceutical innovation in Saudi Arabia. The agreement, signed by the CEOs of both companies, Jérôme Cabannes & Yasser Joharji, & sponsored by the Chairman of SPIMACO Ahmed Aljedai, aims to enhance the accessibility of innovative medicines, drive patient-focused initiatives, and support Vision 2030’s healthcare goals. This partnership represents a shared commitment to improving healthcare and enriching the lives of communities across the region. Together, we are shaping the future of healthcare! #SPIMACO #NahdiMedicalCompany #CPHI

Sanofi Boosts Preparedness With $600 Million Singapore Plant. Sanofi SA added a new plant in Singapore to make vaccines and other medicines, as the French pharmaceutical group seeks to bolster preparedness for emergencies, including potential pandemics. The facility, named Modulus , came up at investment of S$800 million (nearly $600 million) at Tuas Biomedical Park in the city-state, according to a statement... Check out the full story 👉 https://zurl.co/bio271124 (BNN Bloomberg) #sanofi #medicine

Lxbio Pharmaceuticals, a pioneering biotech company founded in 2021, is dedicated to developing and commercializing innovative biopharmaceutical solutions globally. Headquartered in Lisbon, Portugal, Lxbio recently participated in the Abu Dhabi Global Healthcare Week 2024, showcasing their commitment to: - Partnering for Progress: Seeking collaboration with partners in the MEA region to expand their reach and impact. - Embracing Innovation: Lxbio leverages cutting-edge technologies like bacteriophages to unlock new possibilities in healthcare. Lxbio is driven by a clear mission: to improve the quality of life for all by discovering and developing biopharmaceutical solutions that address unmet medical needs. Focus Areas: - Diabetic Foot Infections: Lxbio's lead product is a bacteriophage cocktail targeting Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii, offering a promising alternative to antibiotics for chronic wound infections. This Fast Track designated product is currently in Phase IIb clinical trials. - Respiratory Infections: Lxbio explores bacteriophage cocktails for hospital-based treatment of nosocomial infections, potentially improving patient outcomes. - Spinal Cord Injury and Neuropathic Pain: Lxbio investigates innovative therapies to stimulate nerve recovery and alleviate chronic pain. Their spinal cord injury product is currently in Phase II clinical trials, while the neuropathic pain therapy is in the discovery phase. - Diabetic Retinopathy: Lxbio is developing single-domain antibodies for a topical eye drop treatment targeting various stages of diabetic retinopathy. This project is currently in the discovery phase. Lxbio Pharmaceuticals is at the forefront of biopharmaceutical innovation. By collaborating with global partners and continuously exploring new frontiers in biotechnologies, Lxbio aims to transform healthcare and improve patient well-being worldwide. #portugal #abudhabi #middleeast #business #investment #healthcare #biopharma #marketaccess #governmentalaffairs Portuguese Business Council - UAE

🚀 Top Pharma Companies by Country 🌍 A recent survey highlights the top-ranked pharma leaders across 13 key markets,participants rated the 34 largest pharmaceutical companies globally based on Trust & Like Scores (TLS)–a highly rated brand and reputation attributes. Here’s a quick snapshot: 🇺🇸 US – Bayer, J&J, Eli Lilly 🇬🇧 UK – Bayer, GSK, Moderna 🇯🇵 Japan – Astellas, Daiichi Sankyo, J&J 🇨🇳 China – Bayer, Novo Nordisk, Roche 🇧🇷 Brazil – J&J, Roche, Bayer 🇩🇪 Germany – Boehringer, Novartis, Roche 🇫🇷 France – Roche, Sanofi, Merck #top2024pharma #FDA #MHRA #HealthCanada #TGA #EMA #PMDA #NMPA #CDSCO #ANVISA #MFDS #Roszdravnadzor #COFEPRIS #SAHPRA

2024 Türkiye Pharmaceutical Industry Report, prepared by IQVIA with the support of the Association of Research-Based Pharmaceutical Companies (AIFD) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), has been released. This report provides valuable insights into sectoral trends and growth opportunities, offering a comprehensive analysis to better understand Türkiye's strategic position in the healthcare industry. It presents current data on Türkiye’s pharmaceutical industry, along with objective comparisons with other countries worldwide, while also highlighting the challenges Türkiye faces. It particularly highlights the trends in access to innovative medicines over the past five years and the trajectory of healthcare spending. Greater access to innovative medicines is essential not only for addressing patient needs but also for enhancing Türkiye's potential in the global healthcare arena. At Novartis, we are committed to improving access to innovative medicines and advancing better health outcomes, in collaboration with all our stakeholders. I would like to express my gratitude to everyone who contributed to the preparation of this important report and acknowledge its valuable impact on the industry. #AİFD #PharmaIndustry https://lnkd.in/dZ_MsT99

🗓️ Yesterday i had the oppurtunity to attend 1st SFEE Summit organised by The Hellenic Association of Pharmaceutical Companies (SFEE) at the📍Megaron International Conference Center in Athens. 🇬🇷 🔍 Theme: “Redefining Value” and 📈 Focus Areas: • Greek Economy: Exploring the value of the pharmaceutical industry • Innovation: Discussing the role of pharmaceutical innovation • Healthcare Trends: Unveiling the latest trends in healthcare and pharma • Challenges & Opportunities: Addressing the Greek pharma sector’s challenges and opportunities 🚀 It was a great summit which facilitated in-depth discussions, explored solutions, and shared best practices to current challenges in pharmaceutical landscape while shaped the future of the pharmaceutical policy in Greece 🌿 🔗Last but not least, it was a great oppurtunity to connect with colleagues across healthcare industry during networking breaks #SfEE #SfEESummit #RedifingValue

🚀Novel Drug Approvals: August 2024 Highlights 🚀 The pharmaceutical industry continues to make significant strides in advancing healthcare, and August 2024 has been a month of remarkable progress with as many as ten new drug approvals in different indications! Recent approvals underscore the dynamic nature of our industry and the relentless drive towards innovation and patient care. 💊 Highlighting this month’s progress, the USFDA approved six new medicines, and the EMA approved four. The number of drugs approved significantly increased compared to July 2024. 🌟Key companies securing approvals - #Takeda #JohnsonandJohnson #Incyte #Gilead #Galderma #Ascendis #Servier #Roche #ARSPharma For further information, feel free to connect with Nishu Sharma, Amit Arya, PhD, and Simrat Kaur Stay tuned for more updates on the latest in pharmaceutical innovations! 📈 AdametNext